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This is the third article related to a review of the literature based on data from national cystic fibrosis (CF) patient registries up to June 2008 and
covering a total of 115 published studies. It focuses on several topics: CF incidence, genotype/phenotype correlation, microbiology, pregnancy/
paternity, clinical complications, lung transplantation, and others.
Seventy seven papers meeting the inclusion criteria were found to be related to the topics listed above. Another seven studies, already
evaluated in previous papers of this series, were recalled for specific topics.
Incidence is described by several studies, results being quite different from one country to another and quite inhomogeneous among regions within
the same country. Studies on genetics address the genotype/phenotype correlation and look for a predictive value of CFTRmutations in terms of clinical
outcome, with controversial results. Papers on microbiology describe the clinical relevance of different pathogens and their role in the progress of CF
lung disease. A few articles give information on the features of CF women undergoing a pregnancy and try to identify the ones associated with a better
outcome. Studies on clinical complications discuss prevalence and the role of haemoptysis, pneumothorax, CF related diabetes, ABPA and cancer.
Papers on lung transplantation focus on models able to improve the selection criteria for transplantation candidates and the factors linked to post
transplantation survival. Finally, several studies deal with a number of interesting topics related to CF epidemiology: clinical trial methodology, quality
of care comparison among countries and centers, relationship between diagnosis and age/gender, and evaluation of pharmacological therapy.
On the whole, CF Registries have already contributed to important advances in the knowledge of the natural history of CF, establishing the
foundations for future improvement in CF research and care.
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Registries are considered essential tools designed to measure
and survey all health-related aspects of cystic fibrosis (CF) and to
compare clinical data from different centers and different
countries. Over the last 25 years several national registries of
CF patients have been set up. However, such registries have been
poorly coordinated and major differences exist in terms of
structure (i.e. one data set per patient per year vs. collection of all
out-patient visits or only diagnostic data vs. information also on
treatment) and/or organization (i.e. registries funded by public
health services or CF foundations vs. pharmaceutical companies).
A fair number of publications have been produced by these
registries. We have already provided reviews regarding mortality
and survival [1] and neonatal screening, nutritional status and
growth [2]. This third and last review regards multiple topics that
have been addressed by national CF registries:- CF incidence
- Genetic issues
- Pregnancy and paternity
- CF microbiology
- Clinical complications
- Lung transplantation
- Miscellaneous.2. Methods
The procedure of literature analysis, inclusion and exclusion
criteria were already described in previous articles [1,2]. A
search in Pubmed and Embase up to the cutoff date June 30,2008 was carried out with the following strategy: (“Cystic
fibrosis”[MESH] AND (“Registry”[MESH]) OR registr$).
Furthermore, the contact persons of the most important registries
were interviewed using a questionnaire. A total of 115 studies
were thus analyzed, using a grid developed by the participants
attending a training course of preparation to this analysis process
[1]. Eighty-four papers were selected to review the topics dealt
with in the present article.3. Results and discussion
3.1. Disease incidence
The estimate of the incidence of CF is one of the main
objectives of registries. This is very complicated for various
reasons, including incomplete representativeness of the refer-
ence population; heterogeneity of disease presentation (late
diagnoses, missed diagnoses because of early death), differ-
ences in the ability to identify the disease because of errors or
limitations of diagnostic tests (e.g. false negative sweat test),
incomplete genetic analyses, neonatal screening of only part of
the population, unreported or misclassified cases.
A “genetic” approach, addressing the impact of F508del on
mutational heterogeneity and the incidence of classical CF, was
more conclusive [3]. Adopting a strategy of mutational arrays
and examination of trends in mutation distribution as a function
of ethnic and geographic factors, researchers found a significant
relationship between F508del prevalence and CF incidence: the
variability in CF incidence among countries correlated with the
variability in F508del mutation prevalence; in addition, the
incidence of CF was not influenced by CFTR mutations other
73D. Salvatore et al. / Journal of Cystic Fibrosis 10 (2011) 71–85than F508del, when mutations with a prevalence higher than
0.5% were taken into consideration.
The main analyses relating to the estimate of the incidence of
CF regard the Canadian (4–5) Ecuadorian [6], French [7,8],
Irish [9], Italian [10,11], Swedish [12] UK [13], and US [14,15]
registries (Table 1). Some papers [4,8,10,12,14], in which the
data on incidence of CF were reported within a more general
epidemiological analysis of the registries, have already been
quoted in a previous article of this series [1]. The estimated
incidence varies considerably among different countries and,
within countries, among different regions, also according to the
ethnic groups included (Table 1).
Starting from Europe, the French registry produced two
papers: the study by Scotet et al. [7] assessed the incidence in
Bretagne, a region of Celtic origin with a high incidence of CF
and characteristic CFTR mutations. Bellis et al. [8] reported an
incidence of 1:4600 in France over the period 1994–2003, but
only among 60% of the CF population in France.
In Ireland the CF incidence [9] was 1:1353. This study
showed that the delays in diagnosis were longer when the
patients had respiratory rather than gastrointestinal symptoms.
Moreover, girls were diagnosed later than boys, especially girls
presenting with respiratory symptoms. The high incidence and
older age at diagnosis, as well as gender-related disparities,
justified national newborn screening.
The Italian situation was analyzed in two papers. In the first
[10] the estimated incidence was 1:4700, significantly lower
than in other European and North American countries, and was
found to vary considerably among regions. A later paper in
2003 [11] reported an annual incidence of 1:4298 births and
confirmed the high variability among regions, which led the
authors to speak of “diagnosis incidence” instead of “diseaseTable 1
Disease incidence studies.
Year Registry Patients Main results
2007 Ecuador 62 Incidence and prevalence of 29 most com
2007 France 4104 Mortality and other demographic indicato
2007 Ireland 649 Incidence, age at diagnosis and cost of di
2005 Canada Not available Incidence of CF in Canada over 1971–20
of availability of genetic testing for CF
2004 Italy 1742 Incidence of CF in Italy and changes ove
Comparison with other CF registries and
2002 France 543 Incidence in Bretagne, geographical distri
and CFTR mutation spectrum
1999 Italy 3617 Regional distribution of patients, incidenc
basis for diagnosis, age at death
1998 USA - CFF 17,755
Caucasian
601 Afroamericans
Comparison of incidence, clinical status a
Caucasian and Afro-American US CF pat
1997 UK 6657 Incidence, population, and survival
1996 Canada 3795 Incidence, prevalence and mortality
1996 USA-CFF 19,781 Development of a statistical model to eva
USA, taking into account possible undere
of deaths occurring before diagnosis. Evid
1982 Sweden 116 Incidence and survivalincidence”. Differences in CFTR mutation prevalence are
unlikely to explain such a variability, which is more reasonably
explained by differences in diagnostic approach (higher
incidence in regions with neonatal screening).
The Swedish analysis [12] related to the decade 1968–1977
estimated that the incidence was between 1:2200 and 1:4500.
In the UK Cystic Fibrosis Survey (UKCFS) the average
proportion of CF births between 1968 and 1987 was 1:2415, with
a slight increase in the average incidence over the period, due to
the initial underestimate of cases diagnosed later in life [13].
In America, the incidence in Canada was assessed in two
studies. The first one, by Corey [4], estimated an incidence of
1:2500 live births, with important regional differences. Dupuis
et al. over the period from 1971 to 2000 [5] observed a declining
trend starting from 1988. The offer of genetic testing, with more
widespread diagnosis of carriers and more frequent prenatal
testing would explain this phenomenon, as well as demographic
changes due to an inflow of groups with a lower prevalence of
CFTR gene mutations. Valle et al. [6] reported an estimated CF
incidence of 1:11,252 in the population of Ecuador and one of
the highest incidences of G85E in the world (8.9%). Starting
from the data of the registry of the CF Foundation [14], the
authors developed and applied a statistical model designed to
assess the incidence of CF in newborns in the US over the
period 1989–1991, taking the possible underestimate into
consideration and assessing any differences by gender and race
(Caucasian vs. non Caucasian). Also the study by Hamosh [15]
addressed the differences in incidence among different ethnic
groups in the US population.
Our review of the studies on disease incidence highlights
several limitations. They are mainly retrospective analyses
conducted on historical cohorts, which found large differencesPeriod Incidence 1st author Ref
mon mutations 1:11252 Valle [6]
rs 1994–2003 1:4600 Bellis [8]
agnosis 2001–2003 1:1353 Farrell [9]
00; impact 1971–2000 1:2714 in 1971–1987
1:3608 in 1988–2000
Dupuis [5]
r time
regional variability
1988–2001 1:4238 Bossi [11]
bution 1960–1999 From 1:1787 to 1:3482 Scotet [7]
e, age at diagnosis, 1988–1997 1: 4700 overall
1:3000 in Veneto
Bossi [10]
nd genotype in
ients
1994 1:3200 in
Caucasians,
1:15,000 in non
Caucasians
Hamosh [15]
1968–1995 1:2415 Dodge [13]
1970–1989 1: 2500 overall
1:891 in Quebec
Corey [4]
luate incidence in the
stimation because
ence of gender gap.
1989–1991 1:2906 in
Caucasians
1:12,163 in non
Caucasians
Kosorok [14]
1968–1977 da 1:2200 a 1:4500 Kollberg [12]
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same country, often according to the mode of diagnosis (e.g. by
neonatal screening or not). The performance of accurate studies
on the incidence of the disease requires multiple data sources.
An example is the CF study in Bretagne, carried out on data
from the French registry, extensively integrated with data from
other sources (death certificates, hospital discharge forms,
information from genetic laboratories, information on mis-
carriages and abortions, etc.) [7]. Future data from Registries,
especially recordings including accurate mutation analysis
either directly or from other sources [3] could give more
information about the purported decrease in incidence of CF
resulting from carrier testing and screening [5], seemingly
confirmed by a recent regional study in Italy [16].
3.2. Genetics
A large quantity of information has been published on the
CFTR gene, starting from its cloning in 1989 [17]; so far more
than 1600 mutations of the gene have been identified [18]. This
wealth of molecular genetic information on CF needs to be
associated with similar progress in the field of clinical
interpretation, as the percentage of particular mutations in a
few small populations or in single individuals is very high, often
making the correct definition of their clinical meaning very
difficult. We found 15 studies on this topic (Table 2).
3.2.1. Mutation frequency and clinical significance
Feingold et al. [19] observed the distribution of three
genotypes (F508del/F508del, F508del/other, other/other) in the
American, Canadian and French populations. In all the registries
there was a significant discrepancy between the expected andTable 2
Genetic studies.
Year Registry Patients Main results
2006 USA-CFF 15,651 Prognostic value (mortality) o
high risk genotype vs. low ris
2005 France 39 3849+10KbC-NT
88 2789+5 G-NA
Genotype–phenotype correlat
(3849+10KbCNT e 2789+5
2005 UKCFD 50 Asian
143 Caucasian
Genotype - phenotype correla
2004 France 3220 (114 long survival) Genotype–phenotype correlat
2004 France 8228 alleles Comparison incidence and cli
5 most common mutations in
2004 France 56 Genotype/phenotype correlati
2004 USA-CFF 17,871 Correlation between pancreati
2003 USA-CFF 17,853 Comparison of mortality amo
in heterozygosis with F508de
2002 France 20 Genotype–phenotype correlat
2002 USA-CFF 2605 Frequency of the 25 main CF
2001 Europe-ERCF 8963 Comparison of the frequency
manifestations in patients wit
2000 France 2666 Frequency and distribution of
1999 France 2666 (369 with MI) Allele and genotype frequenc
1998 France 10,988 USA,
2076 Canada
2666 Francia
Distribution of F508del/F508
1996 USA-CFF 20,198 (815 with polyposis)
19,383 controls
Clinical characteristics and ge
treated surgicallyobserved frequencies of the various genotypes, with an excess of
prevalence in F508del homozygotes. The authors support the
hypothesis of selection bias: F508del homozygotes, needingmore
assistance (“severe” genotype), may undergo more screening for
CFTR mutations than other types.
Koch et al. [20], using data from the European registry
(ECFR), compared the frequency and severity of the main clinical
manifestations in patients with different classes of mutations
including class I homozygotes, class II homozygotes, class III
homozygotes, heterozygotes with class II and III mutations, and
heterozygotes with class IV and V mutations. Carriers of class IV
or V mutations had the best outcomes by far.
McKone et al. [21] compared the mortality rates in US
patients with the 11 most common mutations in heterozygosis
with F508del as compared to F508del homozygotes. The largest
differences were found among patients with class IV or V
mutations vs. patients with class II mutations. The authors also
pointed out the notable phenotype variability within the same
genotype, to be ascribed to other factors, both genetic and non
genetic.
McKone et al. [22] studied the prognostic value of genotype
in US patients, i. e. the survival differences in patients with
“high risk” (HR: both alleles belonging to functional class I, II
or III) and “low risk” genotypes (LR: at least one class IV or V
allele). An attempt was made to define what phenotype
characteristics could explain the association between genotype
and survival. Patients with HR genotype had a higher risk of
death than patients with LR genotype (relative risk 2.25, median
age at death 24.2 years vs. 37.6). It is feasible to give a
prognostic value to genotype, although there are other non-
genetic factors that are essential: pulmonary and pancreatic
function, and BMI. Limitations of both the studies are the very1st author Ref
f CFTR genotype in subjects with
k one
McKone [22]
ion for two rare mutations
GNA)
Duguépèroux [30]
tion in the Asian population living in the UK McCormick [24]
ion in long-term survivors Badet [26]
nical CF characteristics for the
France
Duguépèroux [28]
on in patients of the Reunion Islands (Indian Ocean) Duguépèroux [29]
tis and genotype Maisonneuve [34]
ng patients with the 11 most common mutations
l and F508del homozygotes
McKone [21]
ion for the W846X mutation Dugueperoux [27]
mutations for a strategy of prenatal diagnosis Palomaki [23]
and severity of the clinical
h different classes of mutations
Koch [20]
the mutations in the 22 regions of France Guilloud-Bataille [25]
ies in patients with and without meconium ileus (MI) Feingold [32]
del, F508del/x, x/x in US, Canada and France Feingold [19]
notype of CF patients with nasal polyposis Kingdom [31]
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and the selection bias: the patients who live longer are also those
who undergo genotype analysis more easily.
Palomaki et al. [23] studied CF mutations in the non-
Hispanic Caucasian US population to define the panel to use for
prenatal or preconceptional screening. With 25 mutations, the
percentage of carrier identification in the general population
amounted to 88.34%, whereas the detection rate in the
identification of high risk couples was 78%.
McCormick et al. [24] assessed the genotype–phenotype
correlation in the UK population of Asian origin, which
exhibited poorer clinical parameters than Caucasian F508del
homozygotes. In these patients class I and II mutations
prevailed. This difference between Asian and Caucasian
patients could be explained by differences in healthcare access,
which may be more difficult for the former.
Several studies were from the French registry. Guilloud-
Bataille et al. [25] found that the most common mutation in
general was F508del (67.9%), with regional variability and a
trend towards an increase from South-East to North-West. In
view of the variability in the geographic distribution of
mutations, the applicability of carrier screening with a single
panel of mutations is not straightforward. Badet et al. [26]
assessed the clinical and genetic variables of 114 long-term
survivors (diagnosed before age 5 and still alive after age 30),
but did not find any difference as compared to the general CF
population, therefore questioning the impact of genotype on
survival and course of the disease. Finally, 4 studies evaluated
the genotype–phenotype correlation for rare mutations (E60X,
W486X, Y122X, 3849+10KbCNT and 2789+5 GNA) [27–
30]. Unfortunately, the value of these data is reduced by the
very low number of cases studied, so it is to be interpreted with
caution. On the other hand, the importance of these studies from
a local perspective should be taken into consideration, as well as
the possibility of taking these niche populations as a model to
conduct similar analyses in other situations. The data enable
also the acquisition of knowledge on the features of patients
with rare genotypes or belonging to ethnic groups in whom CF
is uncommon.
3.2.2. Mutations and organ-specific aspects
Kingdom et al. [31] studied CF patients with nasal polyposis
treated surgically and disclosed that the prevalence of F508del
homozygosis and F508del/G551D heterozygosis is high among
these subjects; however, no indication is derived about the
particular genotype in patients with nasal polyposis.
Feingold et al. [32] assessed the allele and genotype
frequency in French patients with or without meconium ileus
(MI). The prevalence of MI was 13.8%. The 3 most common
mutations associated with MI were F508del, G542X, and
W1282X. G551D and R117H mutations appeared to be
negatively correlated with MI. It is interesting to observe the
presumptive organ-specific protective effect of the G551D
mutation, which is severe with respect to the channel function of
CFTR and pancreatic function, but negatively correlated to MI
[32] and severity of lung disease, compared to F508del
homozygotes [33].Maisonneuve et al. [34] assessed the relationship between
genotype and pancreatitis, also according to the presence/absence
of pancreatic insufficiency (PI). Patients without PI had a higher
risk of pancreatitis (11.9%), as expected. R334W, amildmutation
that is usually associated with pancreatic sufficiency, was
associated with a 25.8 higher risk of pancreatitis.
The analysis of large case series well characterized from the
genetic point of view could help clinicians implement closer
monitoring and more aggressive treatment in patients with
severe genotypes and to modulate management with a more
permissive attitude in patients with mild genotypes. Moreover,
the recognition of severe and mild genotypes could be useful for
genetic counseling of couples with a high risk of having a CF
child, who need adequate information on CF and its expression,
and therefore, at least in probability terms, on its prognosis.
Finally, genetic epidemiology studies based on CF registries
could facilitate the acquisition of knowledge on the worldwide
distribution of mutation frequencies, thus contributing to both
neonatal and carrier screening programs [3].
However, caution still is required in transferring information
generated from a study population to counseling of patients with
severe genotypes, because the assessments were performed over
relatively short follow-up periods and did not take the
development of therapeutic strategies and longer life expectan-
cy into account. Vice-versa, it is reasonable to accept that
patients with mild genotypes (at least one mild mutation that
enables pancreatic function) have a fairly good probability of a
generally less severe clinical course [22], although the
pulmonary fate of these mild genotypes has not been completely
elucidated.
A new international initiative, called CFTR2 (The Clinical
and Functional Translation of CFTR) project, seeks to provide
complete, advanced and expert-reviewed functional and clinical
information on CFTR mutations. In the long-term, the
completion of this project is expected to have important
implications for diagnosis, prognosis, and therapy selection for
patients and families, particularly for rare CFTR mutation
carriers [35].
3.3. Microbiology
Pulmonary infections are the main problem of CF patients, as
progressive pulmonary dysfunction is the main prognostic
factor. Eight articles focus on this topic (Table 3).
Two studies [36,37] assessed infections by Pseudomonas
aeruginosa (PA). The first one [36], from US data showed that
PA respiratory infection was a major predictor of morbidity and
mortality in children. The second study [37], based on Belgian
data, obtained indications on how to prevent chronic PA
colonization.
Two studies [38,39] regarded chronic infection by Staphylo-
coccus aureus (SA). The first one [38] on German data extracted
from the European Registry of CF (ERCF), found that early use of
continuous prophylactic anti-SA therapy was associated with
higher positivity rates for PA, without any advantage in terms of
clinical course of the disease. The second study [39] used the data
of the ESCF-US study to compare patients with airway infection
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methicillin-sensitive SA (MSSA). It showed that infection by
MRSA worsened pulmonary function and health status of the
patients.
Two papers, from the US registry [40,41], studied the
epidemiology of Stenotrophomonas maltophilia (SM) in CF.
Both the article pointed out the association of SM with more
severe and more advanced disease, but it did not appear to be a
risk factor neither for earlier death nor for decline of pulmonary
function.
Merlo et al. [42] showed that infection by multi-antibiotic
resistant PA (MARPA) was increasing, being more common in
subjects who were older and in worse clinical conditions. Risk
factors were CF-related diabetes, long-term use of inhaled
tobramycin, high prevalence of MARPA at the CF Center
attended and a higher number of pulmonary exacerbations.
Critical issues about pulmonary infection in CF regard
methodological aspects related either to the definition of
colonization/infection or laboratory practices. Chronic infection
in CF is usually preceded by a stage of intermittent infection,
and the early detection of germs (such as PA) followed by
intensive treatment can delay chronic infection. In agreement
with these clinical data, Lee et al. [43] introduced a new
definition, classifying patients into four groups according to
airway culture results obtained over the last 12 months. On the
contrary, any evaluation of prevalence of lung infections
becomes meaningless if laboratory practice does not comply
with recommended guidelines [44]. Further microbiological
studies are needed in the light of the importance of this topic in
the management of CF. Comparisons among different centers
would clarify the value of different therapeutic strategies for CF
pulmonary infection; however, answers could be obtained only
from prospective clinical trials. Recent data from the UK
underline that, despite early diagnosis and excellent care, CF
patients continue to develop a fixed defect in lung function
suggestive of fibrosis, although PA infection further contributes
to this phenomenon [45].
3.4. Pregnancy and paternity
Pregnancy in CF women has progressively become no
longer an exceptional event, but rather an event associated with
particular healthcare needs, also in view of the improved qualityTable 3
Microbiology studies.
Year Registry Patients Main results
2007 USA-CFF 4293 (341 with MARPA infection) Incidence and prevalenc
(MARPA) and risk fact
2007 USA-ESCF 1834 Effect of MRSA infecti
2006 Belgium 116 Characteristics of the pat
2004 USA-CFF 20,755 Effect of S.maltophilia
2002 USA-CFF 19,255 Effect of S. maltophilia
2002 USA-CFF 3323 Prognostic indicators of
2001 Germany 639 Effect of different thera
1999 USA-ESCF 15,328 Comparison of microbio
protocols; relationship b
of the main bacteriaof life and survival of CF patients. On the other hand, the
phenomenon of paternity in CF, related much more than
maternity to fertility issues, has begun to emerge in the last few
years. Five registry studies [46–50] have been published on this
topic between 2002 and 2006 (Table 4).3.4.1. Pregnancy
Goss et al. [46] observed that CF women (680 of the 8136
women in the US cohort studied) who got pregnant had a better
nutritional status, higher FEV1 (77% vs. 58%) and lived longer
than those who did not. A stratified analysis by FEV1, PA
colonization and pancreatic status shows similar mean life
expectancy in pregnant women as compared to the others.
Boyd et al. [47] assessed overall fertility in CF and the
outcome of pregnancies, including both males and females with
the disease, and related these parameters to post-pubertal health
status. The prevalence of poor respiratory function (FEV1
b50% of predicted) and of diabetes mellitus (DM) increased
after puberty in both genders. Few individuals underwent
assisted fertility treatment (1% of males and 0.5% of females)
and few became parents (1.3% partners of males and 5.7% of
females with CF). Women with CF who underwent a pregnancy
had better respiratory function than those who did not and rarely
were F508del homozygotes, whereas health status in men was
not significantly associated with parenting. The median age at
diagnosis of pregnant women was significantly lower than that
of non-pregnant women. It is presently controversial whether
early diagnosis of CF or advances in antimicrobial therapy and
nutritional support have led to the dramatic improvement in
health, and therefore, life expectancy. The change in median age
at diagnosis (0 years vs. 2 years), that corresponds to better
pregnancy outcome, is both statistically significant and
clinically relevant. Lowest median age at diagnosis is now
almost universally available through the use of newborn
screening that, from this point of view, might be the most
appropriate intervention to increase also the number of
pregnancies in CF women. Women who achieved a pregnancy
were significantly less likely to be homozygous for F508del.
The implication is that it may be possible to predict fertility and
reproductive outcomes according to individual genotype.
Unfortunately, no further data are available about this important
issue from other registries.1st author Ref
e of infection due to PA multiresistant to antibiotics
ors for the acquisition of MARPA in CF
Merlo [42]
on on pulmonary function Ren [39]
ients attending a CF center with a low PA colonization rate Lebecque [37]
colonization on pulmonary function Goss [41]
colonization on survival Goss [40]
morbidity and mortality for CF children Emerson [36]
peutic strategies against SA on the PA acquisition rate Ratjen [38]
logy laboratory practices of centers with official
etween adherence to recommended practice and prevalence
Shreve [44]
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the French Registry resulted in 64 newborn babies, out of whom
45 were full-term, and 30% were underweight. There were 5
miscarriages and 5 therapeutic abortions, without any stillbirths.
No differences in respiratory function were found between
pregnant and non-pregnant women. Out of the 12 deaths that
occurred after pregnancy, only 3 occurred within 1 year after
delivery and all women had pre-pregnancy FEV1 b50%.
McMullen et al. [49] compared 216 pregnant women to
matched non-pregnant CF women in 3 different periods: at
baseline, during pregnancy and during follow-up after delivery.
During pregnancy the women had higher exacerbation and
hospitalization rates; DM doubled its prevalence during
pregnancy as compared to baseline. Over the whole study
period (gestation phase and 18 months after delivery) respira-
tory function tended to diminish both in pregnant and non-
pregnant women. After delivery, about half of the cases of
pregnancy-induced DM resolved. The paper does not give
information on the prevalence of breast-feeding or on changes
in compliance to therapy over the observation period, so it is not
possible to establish whether these factors play any role in the
reduction in respiratory function.
In conclusion, the various authors agree on the main result:
pregnancy in CF is an event that can be experienced with a good
chance of a positive outcome for both mother and child. A good
outcome can be achieved provided that pregnancy is adequately
planned, so that the mother is in the best clinical conditions
especially in terms of pulmonary function both during
pregnancy and after: in particular, considerable attention should
be given to the development of DM [47,49]. The CF team
should co-operate closely with obstetricians and neonatologists
to ensure the satisfactory progress of the pregnancy.3.4.2. Paternity
In a French study [50] patients who became fathers were
compared with a group of CF patients who did not. 48 men had
69 children, a fourth of whom “reportedly” by natural
conception, whereas 69% resorted to assisted reproduction
techniques. In the 3 years after becoming fathers the health
status of the patients did not change. These data are still limited
and probably suffer from imprecision in data reporting: the high
percentage of reportedly “natural” paternities is surprising.
However, the topic is to be addressed further in the future, as the
number of adult males in reasonably good health is increasing,
as well as usage of assisted reproduction techniques.Table 4
Pregnancy and paternity studies.
Year Registry Patients Main results
2006 France 48 male Consequences of pat
2006 USA-ESCF 216 pregnants
3896 controls
Prognosis and therap
2004 UKCFD 4659 Fertility in CF men a
2003 USA-CFF 680 pregnants
3327 controls
Effect of pregnancy
2002 France 80 pregnants Consequences of pre3.5. Clinical complications
Complications occur more and more frequently as survival
increases. A total of 10 articles addressing the most common
clinical complications of CF were found (Table 5).
In the long-term (10 years) observational studies by Flume
et al. [51,52], the risk factors, prevalence and long-term
prognosis of major hemoptysis (MH) and pneumothorax
(Pnx) were assessed. MH became more common as the patient
aged and as pulmonary impairment became more serious, and
was associated with SA infection (OR 1.3). Also Pnx became
more common as the patient aged and was associated with more
severe pulmonary function impairment and the presence in
sputum of PA (OR 2.3), B. cepacia (BC) (OR 1.8), Aspergillus
fumigatus (OR 1.3), and FEV1 b30% of predicted (OR 1.5).
Both MH and Pnx were associated with a higher morbidity and
mortality in the 2 years after the episode occurred.
Regarding diabetes mellitus associated with CF (CFRD),
three studies [53–55] addressed this complication. They all
stressed the negative effects of CFRD on nutritional status [53]
and on respiratory function [53–55], especially in women,
albeit with a latency of about 1 year vs. the onset of CFRD [54].
The prevalence of CFRD is very high starting from adolescence
(12–17% of patients) and is more associated than other
complications with a decline in pulmonary function and
nutritional status, particularly in females. These results,
obtained by a cross sectional design in the Sims et al. study
[55], are fully confirmed by the study of Milla et al. [56] in a
prospectively followed cohort. The longitudinal design is
usually considered more reliable than the cross-sectional design
in detecting developments or changes in the characteristics of
the target population that are more likely to indicate causal
relationships. In this case, the natural history of the disease is so
clear-cut that results do not differ according to study design.
CFRD has a significant impact also on survival, as already
shown in the model by Liou et al. [1,57] and documented by the
study by Koch et al., based on data from the ECFR [53].
The topic of Allergic Bronchopulmonary Aspergillosis
(ABPA) is discussed in two studies [58,59]. The ESCF study
[58] showed that the general prevalence of ABPA was 2%, rates
being higher in women, adolescents and subjects with poor
pulmonary function, asthma and cultures positive for PA. An
ERCF study [59] reported a prevalence of ABPA of about 8%.
This discrepancy suggests that diagnostic parameters may be
incomplete in US centers. In the European study ABPA
occurred mainly after 6 years of age, independently of gender,1st author Ref
ernity in CF subjects Duguépéroux [50]
y in pregnant CF women McMullen [49]
nd women and outcome of pregnancies Boyd [47]
on survival Goss [46]
gnancy in CF women Gilet [48]
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with worse general conditions. However, over the 4 years of
follow-up of that study, the CF population with ABPA did not
experience more decline in FEV1 than patients without ABPA,
stratified by age and respiratory function. The prevalence of
complications, such as CFRD and ABPA, shows a large amount
of variability. Besides possible cohort differences, an important
methodological issue should be considered: the differences in
the mode of diagnosis (mainly in definition of the variables
between registries) and in suspecting the diagnosis or in
systematically monitoring of the events.
From the UK CF Survey and US registries we have two
studies regarding stenosing colonopathy [60,61]. These studies
found an association between this condition and the intake of
high doses of pancreatic extracts, suggesting that the dose of
10,000 units of lipase per kg daily should not be exceeded [61].
However, publication of the UK study [60] was followed by
several comments about the unreliability of the report [62].
Moreover, UK CF Database data showed that in 17 UK CF
centers, the recommended dose of lipase was commonly
exceeded at all ages [63]. CF registries will play a crucial role
in defining the relationship between large doses of enzymes and
the prevalence of fibrosing colonopathy.
The case–control study by Neglia et al. [64] regarded the risk
of cancer in CF patients, based on data collected in North
America and Europe between 1985 and 1992. In this study there
was clear evidence of an excess of digestive tract cancers (OR
6.4–6.6) but not of any other type of cancer. Many of these
patients were in their third decade of life at the time of the
diagnosis of cancer. The elevated relative risk of digestive
cancer in young patients with CF is confirmed by the paper [65]
on US data from 1990 through 1999, comparing transplanted
and non transplanted CF patients: an increase in the risk of
cancer of the digestive tract was reported, especially cancer
involving the small intestine, the colon and the biliary tract [23Table 5
Clinical complications studies.
Year Registry Patients Main results
2005 UKCFD 2231 Respiratory consequences of
2005 USA-CFF 1153 Risk factors, prevalence and
2005 USA-CFF 965 Risk factors, prevalence and
2005 USA-ESCF 8247 N13 years
1180 diabetic
Prevalence of diabetes in CF
2003 USA-CFF 1063 transplanted
(901 PT),
28,858 controls
Risk of cancer in transplanted
2001 ERCF 7566 Consequences of diabetes on
2001 USA-CFF 5820 Development and validation
2000 ERCF 12,447 Prevalence of ABPA, associa
1999 USA-ESCF 14,240 Prevalence of ABPA in Nort
demographic and clinical dat
1997 USA-CFF 29 cases
105 controls
Relationship between pancrea
1995 UKCFD 14 cases
56 controls
Relationship between therapy
1995 USA–CFF Canada CF
European Association
25,000 US,
3000 CDN,
24,500 EU
Relationship between CF andcases observed vs. 4 expected cases: SIR (standardized
incidence ratio)=5.1,]. As in non-transplanted CF patients,
there was a statistically significant increase in the number of
digestive tract cancers (4 cases observed vs. 0.19 expected;
SIR=21.0). As expected in an immuno-suppressed population,
several patients developed malignant lymphoma (7 cases
observed vs. 0.16 expected; SIR=43.8). Whether transplanta-
tion is a further risk factor for cancer in CF is not discussed by
the authors. The small number of cases and the very wide 95%
CI for each cancer site suggest that further data are needed
to address the issue appropriately. As survival of the CF
population continues to improve, these findings could help
identify subgroups of patients who are more likely to develop
digestive tract cancer and for whom screening for digestive tract
cancer could be beneficial.
3.6. Lung transplantation
Chronic progressive pneumopathy is the main negative
prognostic factor in CF patients. Transplantation science has
given an important therapeutic option to subjects in the severe
and irreversible phase of pulmonary disease, in which
conventional medical treatment has little to offer. CF is the
main indication for double lung transplantation (PT) in children
over 5 years of age and the third indication in order of frequency
in adults, as reported in the registry of the International Society
for heart & lung transplantation [66,67]. These comprehensive
data, regarding several different diseases, however, need to be
integrated by further information about PT in CF, in view of the
specific features of CF patients. We report four studies that
address this topic [68–71] (Table 6).
The primary objective of the study by Liou et al. [68], a
retrospective study carried out on 468 transplanted patients and
11,630 controls, was to measure the effect of PT in terms of
survival. A multivariate logistic regressionmodel was performed,1st author Ref
diabetes in CF patients; influence of gender Sims [55]
prognosis of patients with major hemoptysis Flume [51]
prognosis of patients with pneumothorax Flume [52]
and influence on prognosis Marshall [54]
and non transplanted CF patients Maisonneuve [65]
respiratory function, BMI and body weight for age Koch [53]
of a 5-year survival model. Liou [57]
tion with clinical conditions Mastella [59]
h America, according to
a
Geller [58]
tic enzymes (dose and type) and fibrosing colonopathy FitzSimmons [61]
with pancreatic enzymes and fibrosing colonopathy Smyth [60]
appearance of cancer Neglia [64]
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probability of a 5-year survival based on 9 variables: gender, age,
weight z-score, pancreatic insufficiency, CFRD, SA and BC
infection, number of annual exacerbations and FEV1 value.
Advantages in terms of post-transplantation survival were found
only for patients in whom the estimate of a 5-year survival was
less than 30%. In this subgroup, shorter survival in the first
6 months after PT was recorded, but thereafter there was a clear
advantage in terms of survival 2 years after PT as compared to the
control group. Small advantages were recorded also in the group
with a survival probability between 30 and 50%, whereas a
definite disadvantage was reported in transplanted patients with a
probability N50%.
In another study by Liou et al. [69] the assumption was that
the use of a model able to assess post-PT survival may improve
the selection of candidates for PT. A multivariate Cox model
was used to select the variables that influence post-PT survival.
Among the 24 considered variables, 3 patient-specific factors
had an impact on post-PT survival: CF-related arthropathy (of
doubtful classification and clinical meaning), BC infection in
adults (predicted 5-year survival b50%), but not in children,
and, finally, age, as the risk of death seems to diminish as age at
transplantation increases to such an extent that a rigid cutoff of
18 years has been suggested for PT. Based on the model
proposed, PT is a priority for patients older than 18 years with
an estimated survival of less than 5 years and devoid of BC
infection. This study of notable importance admittedly has some
limitations typical of studies carried out on historical cohorts,
such as its retrospective design, the selection of an incomplete
set of variables (e.g. hypercapnia and the genomovar of the BC
complex are not included) and the fact that selection criteria for
PT candidates changed over time: see the different course of
survival after PT from 1991 to 1997 (217 deaths out of 473
transplanted patients) and from 1998 to 2001 (87 deaths out of
372 transplanted patients).
A third retrospective study by Liou et al. [70] compared
1992–2002 data of the US CFF registry with 1998–2004 data of
Organ Procurement and Transplantation Network. The primary
objective of this study was to assess the effect of PT in terms of
improvement in survival in CF patients younger than 18 years
of age. This study did not detect a significant benefit in terms of
survival in most of the children who underwent PT. BC
infection caused a reduction in survival both before and after
PT. CFRD caused a reduction in survival before PT, but not
after. Older age reduced survival after PT, but not during the
period on the waiting list; the same was true for SA infection.Table 6
Transplantation studies.
Year Registry Patients Main results
2007 USA-CFF 514 Effect of PT (survival) in patients b
2005 USA-CFF 845 transplanted
11,630 controls
Variables that influence survival af
2002 USA-CFF 278 transplanted
11,630 controls
Clinical predictors of 2-year morta
2001 USA-CFF 468 transplanted
11,630 controls
Impact of bilateral lung transplantaThree parameters (age, CFRD and SA infection) were used to
assess the risk or benefit defined as “proportional hazard for
death” related to PT. Only 5 patients out of 514 experienced a
clear benefit and an increase in survival after PT, whereas 315
patients experienced an increase in the risk of adverse effects,
76 a non significant benefit and 118 a non significant risk of
harm associated with PT. The limitations of the retrospective
design once again stress the need for a prospective study in
order to clarify whether PT may improve the survival and
quality of life of CF children and, if so, to what extent.
The objective of the study by Mayer-Hamblett et al. [71] was
to develop a model able to identify the best clinical factors able
to predict the 2-year risk of death, as this is the realistic waiting
period, thus contributing to the selection of PT candidates.
Some clinical factors resulted to be good predictors of a 2-year
mortality: number of hospitalizations, number of antibiotic
cycles at home due to exacerbations, BC colonization, PA
colonization, body weight, height and age, and FEV1; race and
gender appeared not to be. Also in this study, age was a
predictor of the 2-year mortality after PT with a turning point at
21 years of age, always to the detriment of younger patients.
Moreover, this study compared the prognostic accuracy of the
proposed analysis model based on the criterion of FEV1 b30%.
Both show a high negative predictive capacity (98% vs. 97%),
but a low positive predictive value (33% vs. 28%). In
conclusion, a good clinical indicator of short-term mortality
that could be useful for the selection of candidates and
indication of PT, has still to be identified.
In response to controversies about the survival benefits of
PT, a consensus conference was organized with the objective of
ascertaining the state of the art in PT for CF within an
international context, focusing on advances in surgical
techniques, measurement of outcomes, use of prognostic
criteria, variations in local control over listing, prioritization,
patient adherence before and after transplantation and other
issues within the broader context of PT. Experts from the US,
Canada, UK, and The Netherlands carefully considered how
efforts to improve the outcome of PT for CF lung disease might
best be studied, bearing in mind that improvements should
focus on candidate selection criteria and optimized timing of
referral for transplantation [72].
3.7. Miscellaneous
The analysis of the literature deriving from CF Registries
provided a series of other scientific papers that addressed1st author Ref
18 years according to some prognostic factors Liou [70]
ter transplantation Liou [69]
lity Mayer-Hamblett [71]
tion (PT) on survival in CF patients Liou [68]
Table 7
Miscellanea studies.
Year Registry Patients Main results 1st author Ref
Comparison between registries
2005 UKCFD, USA-CFF,
France, Australasia
UK 4689
USA 22,301
France 3388
Australasia
2507
Biographical, anthropometric, FEV1, infection data McCormick [76]
2001 Germany 4306 Morbidity and mortality Wiedemann [79]
1998 France, ERCF 8831 ERCF
1457 France
French patients vs. other European patients Delaisi [75]
1997 ERCF 6858 Use of treatment according to age of patients and extent of respiratory function impairment Koch [77]
1995 France 1739 French vs. Canadian and US patients Rault [74]
1988 USA-CFF, Canada 499 at Boston
534 at Toronto
Patients at Toronto vs. Boston with respect to growth, pulmonary function, and survival Corey [73]
1982 Sweden 116 Swedish patients vs. US. Incidence and survival Kollberg [12]
Clinical trial methodology
2007 UKCFD 1806 Northern Score for chest X-rays McCormick [85]
2006 USA-CFF 8735 Representativeness of CF patients enrolled in clinical trials Goss [81]
2005 USA-CFF 21,646 FEV1 standards for the CF population Kulich [83]
2004 ESCF-USA 11,692 Operational definition of pulmonary exacerbation Rabin [82]
2001 USA-CFF 6832 Mathematical models for FEV1% estimate Rosenfeld [84]
Quality of care, guidelines
2007 USA-ESCF 837 6–12 years
527 0–3 years
Clinical and healthcare variables related to better clinical conditions Padman [89]
2003 USA-ESCF 4151 Differences in pulmonary status according to differences in monitoring frequency and therapy Johnson [88]
1999 USA-ESCF 12,631 Assessment and monitoring of health status Konstan [86]
1999 USA-ESCF 12,622 Therapeutic intervention Konstan [87]
1994 USA-CFF 427 CF patients, family members US military staff Callahan [90]
Factors influencing CF lung disease
2008 USA-CFF 812 Relationship between secondhand smoke exposure and lung disease severity Collaco [93]
2004 USA-CFF 11,484 Effect of exposure to different levels of atmosphere pollution in CF Goss [92]
2001 ERCF 7010 Relationship between risk factor exposure and Pneumopathy Navarro [91]
Factors influencing diagnosis
2006 UKCFD 3851 Relationship between delay in diagnosis in females and clinical outcome McCormick [95]
2002 USA-CFF 11,275 Relationship between age at diagnosis and clinical conditions,
differences between males and females
Lai [94]
2000 USA-CFF b18 years 6641
N18 years 786
Clinical and demographic parameters of patients diagnosed before and after 18 years Widerman [96]
Therapeutic strategy evaluation
2007 ERCF 6829 Effects of DNase McKenzie [99]
2007 USA-CFF 10,325 Impact of ibuprofen treatment on FEV1 Konstan [101]
2003 ERCF 13,684 Effects of DNase Hodson [98]
2002 USA-CFF 20,662 The risk of death in subjects given prolonged treatment with inhaled tobramycin Rothman [100]
1999 USA-ESCF 283 cases
2382 controls
Effects of DNase Johnson [97]
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Table 7.
3.7.1. Comparisons among registries
We have already partly carried out comparisons between the
Swedish and the US registry data and between the US and the
Canadian registry data [1,2,12,73]. Here we add further
considerations related to the various comparisons among
registries. Incompleteness of data, differences in the contribu-
tions of the individual countries and heterogeneity among the
various countries in terms of data collection made anyconclusion difficult [74–78] with the exception of the fruitful
comparison between Boston and Toronto [73], which was
previously discussed [2].
The study by Koch et al. [77] was designed to assess whether
the therapeutic approach differed among countries of ECFR.
The efficacy of clinical nutrition on survival was not proved.
Mucolytics were commonly used in Germany (90%), but not
used at all in UK. DNase was commonly used in France (49%),
whereas its use was infrequent in UK (16%). The use of inhaled
steroids ranged from 10% in France to 36% in the UK. These
data recently induced UK researchers to test the safety of
81D. Salvatore et al. / Journal of Cystic Fibrosis 10 (2011) 71–85withdrawal of inhaled corticosteroids; the study showed that it
appears safe to consider stopping inhaled corticosteroids [78].
The variations observed in medication use across countries
are difficult to interpret and could simply be due to a different
ability to pay for drugs. Some countries have extensive
government drug programs covering the cost of expensive
medications while others do not.
An analysis of the German registry [79] was conducted to
improve the quality of care, promote a positive comparison
among centers and assess the efficacy of management.
Comparisons with US and French data were included in the
discussion, but the high rate of German patients lost to follow-
up did not enable any conclusion to be drawn on German
mortality rates.
It is evident that failure to share methods of data collection a
priori (including failure to share definitions of clinical events)
and incompleteness or incorrectness of the available data limits
the value of the registries for comparative studies [75–77,79].
Although on the one hand it may not be realistic to expect that
all registries collect data in a similar way or use the same
universal definitions, on the other hand the point that should be
emphasized is that registries need to be clear about how they
collect data, what definitions are used for the variables
collected, and what quality assurance checks they undergo.
Creating and maintaining a national registry is labour intensive
and can be extremely costly and differences in how registries
are maintained or what data is collected may also differ simply
because of resources available. Recent efforts by the European
Cystic Fibrosis Society to share data collection software for a
European registry appear to be going in the desired direction
[80].3.7.2. Clinical trial methodology
Some registries used the available data also to address
clinical trial methodological issues, especially those related to
recruitment and inclusion of patients.
Goss et al. [81], using CFF-US data, verified whether
patients recruited for clinical trials (CT) are really representative
of the CF populations they derive from. It was found that CF
patients taking part in CT had worse FEV1 than the other
patients (68 vs. 77%), but also experienced lower annual decline
of FEV1 (1.33% vs. 1.55% per year), had a higher prevalence of
PA (71 vs. 65%) and were more frequently Caucasians (OR
1.98). The authors speculate that participation to CT enables a
better global assessment of the clinical conditions of the patients
than routine management or that patients included in CT may
have easier access to treatment.
The study by Rabin et al. [82] attempted to standardize a
definition of pulmonary exacerbation in CF. Starting from
ESCF records, the authors sought the group of variables having
the closest correlation with the decision to give treatment for
pulmonary exacerbation in each age group. Under 6 years of
age the variables were: finding of new crackles upon chest
auscultation, and increase in cough, body weight decline and
increase in sputum. Over 6 years: relative decline in FEV1,
increase in cough, and finding of new crackles and hemoptysis.Also the evaluations related to the analysis of reference data for
the assessment of respiratory function [83,84] indicate the
importance of standardizing the reference equations and the
severity classification used, and of avoiding selection bias in
multicenter studies. In the paper by McCormik et al. [85] there is
the first figure bearing reference values (centiles) for the
radiological “Northern Score”. How this criterion can compete
with serial computerized tomographies remains to be established.
3.7.3. The role of the registry in quality for care and best practice
The study by Konstan et al. [86] was a report on the methods
for assessing and monitoring the health status of CF patients
recruited in ESCF and their adherence to protocols drawn up by
the CFF. In most patients the criteria recommended for the
routine work up of CF were met, but an overall strategy for the
generalized improvement of management is required.
This article continues with another study [87] describing
how CF patients are managed. Generally drugs were more
frequently used in older patients with poorer respiratory
function and PA colonization. Four treatments (oral calorie
supplements, parenteral nutrition, diuretics and pancreatic
enzymes) were more frequently used in males than in females,
notwithstanding the lack of significant differences in pulmonary
and nutritional status.
The article by Johnson et al. [88] assessed differences in
pulmonary status of CF patients at centers in North America and
verified whether such differences were due to differences in the
frequency of monitoring and in the application of management
guidelines. The study suggests that monitoring at shorter
intervals and a higher number of interventions, including the
long-term use of antibiotics by intravenous route, could
determine better outcomes.
The article by Padman et al. [89], attempted to disclose “best
practice” for respiratory treatment at various ESCF centers
where mean FEV1 was the highest in the registry as compared
to the centers with the lowest values. The authors found that
centers with better mean FEV1 visited patients and ordered
bacterial cultures more frequently, had more aggressive
pharmacological approaches (intravenous antibiotics, oral
corticosteroids), but prescribed less physiotherapy and nutri-
tional supplements. This analysis shows that pulmonary
function can be influenced by specific interventions, mainly
during the first years of life. In conclusion, ESCF researchers
acknowledge that the first step in any evaluation of the quality
of care is to gather information on the current status of treatment
practices. It is important to be able to assess the impact of
prescribing patterns on outcomes and monitor subsequent
changes in practice. As a large-scale quality assurance
instrument, the registry will assist CF caregivers in refining
the management of patients, with the ultimate goals of improved
survival and quality of life.
An analysis of patients who were family members of US
military personnel offers a particular evaluation of the
importance of centralized management at a certified CF service
[90]. The study pointed out how many CF patients are ignored
by the CFF-US registry and are picked up occasionally during
contacts with US military services.
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A study on ERCF data [91] assessed risk factors associated
with impairment of respiratory function. The factors associated
with FEV1 values lower than 10% ormore than predicted for age
and gender were: low body weight, hemoptysis, Pnx, pulmonary
symptoms at onset, PA and BC infection, use of oral steroids,
anti-inflammatory drugs, dornase-alpha, oxygen and mechani-
cal ventilation. In patients aged over 12 years, physiotherapy, is
a requirement for oral nutritional supplements, pancreatic
enzymes and insulin or oral antidiabetic agents. Regular exercise
(especially in older patients) and nasal polyposis were associated
with moderately higher FEV1 values than predicted.
Two studies address the effects of polluting agents on US CF
patients. Goss et al. [92], recorded how exposure to various
levels of atmospheric pollution (ozone, NO2, SO2, and CO) was
associated with an increase in the risk of pulmonary exacerba-
tions and more rapid decline of pulmonary function. Collaco
et al. [93] showed that the exposure to passive smoking was
associated with worse respiratory function. Regression analysis
did not show any further influence of socio-economic status,
whereas some genotypes both of CFTR gene and modifying
genes (e.g. TGFβ1) appeared to further amplify the negative
effect of passive smoking.
3.7.5. Factors influencing diagnosis
Lai et al. [94] analyzed age at diagnosis and the clinical
characteristics in the two genders at the moment of diagnosis, in
the patients in the US Registry, as compared to patients screened
at birth in Wisconsin. The issue appears to be the benefit of early
diagnosis, which at that time was championed in the US only by
Wisconsin and Colorado, where neonatal screening was carried
out. Among the patients diagnosed based on symptoms, females
were older than males at diagnosis (median 12.7 vs. 8.7 months).
The delay in diagnosis was more evident in females with
respiratory symptoms (median 40.7 vs. 22.3 months). The authors
set forth various hypotheses to explain the phenomenon, ranging
from the higher frequency of wheezing in males to psycho-social
factors in the US, as this finding does not occur among screened
subjects. They propose newborn screening to cover the gap.
McCormick et al. [95], using the UK registry data, supported
the hypothesis that gender affects the age at diagnosis of CF
patients presenting with respiratory symptoms alone, with
female patients experiencing a median 9 month relative delay
(males at 22 months vs. females at 31 months). Although both
studies [95,96] showed that patients presenting with respiratory
symptoms alone had a significant difference between genders,
the diagnostic delay for UK females was half the delay observed
in the US (9 vs. 18 months). In contrast to the US study,
however, there were no gender differences in clinical outcomes
in this group. The reasons for this delay in the age at diagnosis
remain unknown. The impact of this finding for medical
practice is that the delay does not segregate female patients with
a significantly poorer clinical phenotype compared with their
male counterparts. These data, observed also in the Irish study
[9], further encourage the introduction of newborn screening
programs, independently of attempts to understand the
mechanisms underlying the phenomenon.Widerman et al. [96] set the objective of assessing the
distribution of clinical and demographic parameters among US
patients diagnosed before and after 18 years of age. The patients
diagnosed when they were adults had a lower percentage of
severe mutations and numerous mild forms; their overall
survival was better. This is an indication for the clinician and
researcher alike not to lump patients with CF all together, but
rather to learn to distinguish patients right from the beginning of
every analysis according to factors, such as age at diagnosis,
which may be essential for the clinical characterization and
prognosis of the patients.3.7.6. Therapeutic strategy evaluation
Three studies analyze the effect of rhDNase [97–99]. These
large retrospective studies (which may be considered as phase
IV trials or post-marketing surveys) seem to confirm that
patients benefit slightly from this drug from a clinical point of
view [97,98]. The data also support the good tolerability and
safety profile of the drug in all age groups [99].
Rothman et al., using the CFF-US registry data [100],
assessed the risk of death in subjects given a prolonged treatment
with inhaled tobramycin. It appeared to be higher in patients who
had taken the drug for 4 months or longer (RR 3.5) than in those
who had taken it for shorter periods. However, the RR dropped
to 1.2 by the adjustement of the covariates. The short observation
period (1 year) does not enable the assessment of mortality, to
which many other factors can obviously contribute.
Konstan et al. [101] assessed the impact of chronic treatment
with ibuprofen on annual decline in FEV1 in clinical practice,
based on registry data. Slower rates of FEV1 decline were seen
in children and adolescents with CF who were treated with
ibuprofen. The apparent benefits of ibuprofen therapy out-
weighed the small risk of gastrointestinal bleeding.
The limitations of these studies are that no information can
be obtained on the true period of treatment, the dose actually
taken, adjusted on the basis of individual pharmacokinetics and
compliance to treatment; moreover, only serious adverse events
were reported. The advantage is that the data are related to large
numbers of patients treated for a long period. Moreover, studies
reported here were the first ones based on the CF registry data
and were designed to assess the long-term effects of a new
therapeutic approach on annual FEV1 decline.4. Conclusions
The Patient Registries are an irreplaceable resource for clinical
and epidemiological research in CF. They are fundamental to
identify new trends or an increase in complications or new
infections. The co-operation of CF registries is essential to gain a
better understanding of the disease and its treatment. Moreover,
registries and clinical trial networks should merge their resources
with the aim of achieving high quality clinical trials. From this
point of view, scientific societies (such as ECFS) should address
the issue of competing registries, particularly of registries funded
by non-independent sponsors, by obtaining truly independent
funding that is the only way to avoid any sort of preventive bias.
83D. Salvatore et al. / Journal of Cystic Fibrosis 10 (2011) 71–85In summary, this overview of the literature based on CF
registries has convinced us of the vital importance of registries
in providing guidance regarding organizational and therapeutic
strategies in the future, as long as they join their efforts to
improve the completeness and the quality of their data.
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